Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice

Gloria S. Huang, Lluis Lopez-Barcons, B. Scott Freeze, Amos B. Smith, Gary L. Goldberg, Susan Band Horwitz, Hayley M. McDaid

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: To evaluate the drug combination of discodermolide and Taxol in human ovarian cancer cells and in an in vivo model of ovarian carcinoma. Experimental Design: The combination index method was used to evaluate the interaction of Taxol and discodermolide in human ovarian SKOV-3 carcinoma cells. Data were correlated with alterations in cell cycle distribution and caspase activation. In addition, SKOV-3 xenograft-bearing mice were treated with either Taxol, discodermolide, or a combination of both drugs given concurrently to evaluate the antitumor efficacy and toxicity of this combination. The Matrigel plug assay and CD31 immunohistochemistry were done to assess antiangiogenic effects. Results: Taxol and discodermolide interact synergistically over a range of concentrations and molar ratios that cause drug-induced aneuploidy in ovarian carcinoma cells. In SKOV-3 xenograft-bearing mice, the combination is significantly superior to either single agent, and induces tumor regressions without notable toxicities. Immunohistochemical analysis of CD31 and Matrigel plug analysis show decreased vessel formation in mice treated with the combination relative to either drug alone. Conclusions: The synergistic activity of Taxol and discodermolide in cells is most potent at drug concentrations that result in drug-induced aneuploidy rather than mitotic arrest. Moreover, in an animal model of ovarian carcinoma, this is a well-tolerated combination that induces tumor regressions and suppresses angiogenesis. These data confirm the potency of this combination and support the use of concurrent low doses of Taxol and discodermolide for potential use in cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)298-304
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Paclitaxel
Heterografts
Carcinoma
Aneuploidy
Drug Combinations
Pharmaceutical Preparations
Neoplasms
Caspases
Ovarian Neoplasms
discodermolide
Cell Cycle
Research Design
Animal Models
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. / Huang, Gloria S.; Lopez-Barcons, Lluis; Freeze, B. Scott; Smith, Amos B.; Goldberg, Gary L.; Band Horwitz, Susan; McDaid, Hayley M.

In: Clinical Cancer Research, Vol. 12, No. 1, 01.01.2006, p. 298-304.

Research output: Contribution to journalArticle

Huang, Gloria S. ; Lopez-Barcons, Lluis ; Freeze, B. Scott ; Smith, Amos B. ; Goldberg, Gary L. ; Band Horwitz, Susan ; McDaid, Hayley M. / Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 1. pp. 298-304.
@article{ccd328db0a334fc4b0c47c57a809cf03,
title = "Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice",
abstract = "Purpose: To evaluate the drug combination of discodermolide and Taxol in human ovarian cancer cells and in an in vivo model of ovarian carcinoma. Experimental Design: The combination index method was used to evaluate the interaction of Taxol and discodermolide in human ovarian SKOV-3 carcinoma cells. Data were correlated with alterations in cell cycle distribution and caspase activation. In addition, SKOV-3 xenograft-bearing mice were treated with either Taxol, discodermolide, or a combination of both drugs given concurrently to evaluate the antitumor efficacy and toxicity of this combination. The Matrigel plug assay and CD31 immunohistochemistry were done to assess antiangiogenic effects. Results: Taxol and discodermolide interact synergistically over a range of concentrations and molar ratios that cause drug-induced aneuploidy in ovarian carcinoma cells. In SKOV-3 xenograft-bearing mice, the combination is significantly superior to either single agent, and induces tumor regressions without notable toxicities. Immunohistochemical analysis of CD31 and Matrigel plug analysis show decreased vessel formation in mice treated with the combination relative to either drug alone. Conclusions: The synergistic activity of Taxol and discodermolide in cells is most potent at drug concentrations that result in drug-induced aneuploidy rather than mitotic arrest. Moreover, in an animal model of ovarian carcinoma, this is a well-tolerated combination that induces tumor regressions and suppresses angiogenesis. These data confirm the potency of this combination and support the use of concurrent low doses of Taxol and discodermolide for potential use in cancer therapeutics.",
author = "Huang, {Gloria S.} and Lluis Lopez-Barcons and Freeze, {B. Scott} and Smith, {Amos B.} and Goldberg, {Gary L.} and {Band Horwitz}, Susan and McDaid, {Hayley M.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-05-0229",
language = "English (US)",
volume = "12",
pages = "298--304",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice

AU - Huang, Gloria S.

AU - Lopez-Barcons, Lluis

AU - Freeze, B. Scott

AU - Smith, Amos B.

AU - Goldberg, Gary L.

AU - Band Horwitz, Susan

AU - McDaid, Hayley M.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Purpose: To evaluate the drug combination of discodermolide and Taxol in human ovarian cancer cells and in an in vivo model of ovarian carcinoma. Experimental Design: The combination index method was used to evaluate the interaction of Taxol and discodermolide in human ovarian SKOV-3 carcinoma cells. Data were correlated with alterations in cell cycle distribution and caspase activation. In addition, SKOV-3 xenograft-bearing mice were treated with either Taxol, discodermolide, or a combination of both drugs given concurrently to evaluate the antitumor efficacy and toxicity of this combination. The Matrigel plug assay and CD31 immunohistochemistry were done to assess antiangiogenic effects. Results: Taxol and discodermolide interact synergistically over a range of concentrations and molar ratios that cause drug-induced aneuploidy in ovarian carcinoma cells. In SKOV-3 xenograft-bearing mice, the combination is significantly superior to either single agent, and induces tumor regressions without notable toxicities. Immunohistochemical analysis of CD31 and Matrigel plug analysis show decreased vessel formation in mice treated with the combination relative to either drug alone. Conclusions: The synergistic activity of Taxol and discodermolide in cells is most potent at drug concentrations that result in drug-induced aneuploidy rather than mitotic arrest. Moreover, in an animal model of ovarian carcinoma, this is a well-tolerated combination that induces tumor regressions and suppresses angiogenesis. These data confirm the potency of this combination and support the use of concurrent low doses of Taxol and discodermolide for potential use in cancer therapeutics.

AB - Purpose: To evaluate the drug combination of discodermolide and Taxol in human ovarian cancer cells and in an in vivo model of ovarian carcinoma. Experimental Design: The combination index method was used to evaluate the interaction of Taxol and discodermolide in human ovarian SKOV-3 carcinoma cells. Data were correlated with alterations in cell cycle distribution and caspase activation. In addition, SKOV-3 xenograft-bearing mice were treated with either Taxol, discodermolide, or a combination of both drugs given concurrently to evaluate the antitumor efficacy and toxicity of this combination. The Matrigel plug assay and CD31 immunohistochemistry were done to assess antiangiogenic effects. Results: Taxol and discodermolide interact synergistically over a range of concentrations and molar ratios that cause drug-induced aneuploidy in ovarian carcinoma cells. In SKOV-3 xenograft-bearing mice, the combination is significantly superior to either single agent, and induces tumor regressions without notable toxicities. Immunohistochemical analysis of CD31 and Matrigel plug analysis show decreased vessel formation in mice treated with the combination relative to either drug alone. Conclusions: The synergistic activity of Taxol and discodermolide in cells is most potent at drug concentrations that result in drug-induced aneuploidy rather than mitotic arrest. Moreover, in an animal model of ovarian carcinoma, this is a well-tolerated combination that induces tumor regressions and suppresses angiogenesis. These data confirm the potency of this combination and support the use of concurrent low doses of Taxol and discodermolide for potential use in cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=31544455024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544455024&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0229

DO - 10.1158/1078-0432.CCR-05-0229

M3 - Article

VL - 12

SP - 298

EP - 304

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -